Quarterly ResultMay 4, 2026, 07:00 AM
Krystal Biotech Q1 Revenue $116.4M, Net Income $55.9M
AI Summary
Krystal Biotech reported strong financial results for the first quarter of 2026, with VYJUVEK net product revenue reaching $116.4 million, a 32% increase from the prior year, and a net income of $55.9 million. The company also announced significant progress in its pipeline, including the completion of enrollment for the KB803 registrational study and anticipated data readouts for KB803 and KB801 in 2026. Additionally, the FDA granted platform technology designation for KB407 and KB111, potentially accelerating future development, and the company maintains a robust balance sheet with $1.0 billion in cash and investments.
Key Highlights
- Krystal Biotech reported Q1 2026 VYJUVEK net product revenue of $116.4 million, a 32% increase year-over-year.
- Net income for Q1 2026 was $55.9 million, or $1.91 per basic common share.
- Total VYJUVEK global revenue since launch reached $846.7 million.
- The company ended the quarter with a strong balance sheet of $1.0 billion in cash and investments.
- Enrollment is complete for the KB803 registrational study (IOLITE) with 16 patients, with top-line results expected in 4Q 2026.
- FDA granted platform technology designation for KB407 (Cystic Fibrosis) and KB111 (Hailey-Hailey disease).
- FY 2026 non-GAAP R&D and SG&A expense guidance is $175.0 million to $195.0 million.